Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures

NCT00537940 | Completed Phase 4 Results DMC

• 3 other identifiers: A00811432007-003161-40207103
• Study Type: interventional
• Target: 482
• Locations: 4 countries
• Sites: 8

Brief Summary

To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.

Conditions

Epilepsy; Partial Seizure Disorder; Epilepsies, Partial; Complex Partial Seizure Disorder

Outcome Measures

Primary Outcomes (1)

• Percent Change From Baseline in 28-day Seizure Frequency at Week 21.

  The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure \[SGTC\]).

  6 weeks Baseline, 21 weeks through End of MP for 27 weeks

Secondary Outcomes (8)

• Percentage of Participants With 50% Reduction From Baseline in 28-day Seizure Rate at Week 21.

  6 weeks Baseline, 21 weeks through End of MP for 27 weeks

• Percentage of Participants With 75% Reduction From Baseline in 28-day Seizure Rate at Week 21.

  6 weeks Baseline, 21 weeks through End of MP for 27 weeks

• Percentage of Participants Without Seizures.

  6 weeks Baseline, 21 weeks through End of MP for 27 weeks

• Change From Baseline in the 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Frequency at Week 21.

  6 weeks Baseline, 21 weeks through End of MP for 27 weeks

• Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.

  6 weeks Baseline, 21 weeks through End of MP for 27 weeks

Study Arms (2)

A

ACTIVE COMPARATOR

Drug: Pregabalin

B

ACTIVE COMPARATOR

Drug: Gabapentin

Interventions

Pregabalin DRUG

150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

A

Gabapentin DRUG

300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

B

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects (male or female) must be \> 18 years or ≤ 80 years of age, with a diagnosis of epilepsy with partial seizures, as defined in the International League Against Epilepsy (ILAE) classification of seizures; partial seizures may be simple or complex, with or without secondary tonic-clonic generalization.
• Subjects must be have been diagnosed with epilepsy for at least 2 years, and must have been unresponsive to treatment with at least two but no more than five prior antiepileptic drugs (AEDs), and at the time of study enrollment are on stable dosages of 1 or 2 standard AEDs.
• They must have had a 12 lead electrocardiogram (ECG) without clinically significant abnormal findings prior to randomization.
• Subjects must have had magnetic resonance imaging or contrast enhance computed tomography scan of the brain that demonstrated no progressive structural central nervous system abnormality at the time of the diagnosis of epilepsy.
• Women of childbearing potential must be established on an effective method of contraception during the study. Women should also have a negative pregnancy test prior to study entry.
• During the 6-week baseline period, subjects must have had a minimum of four partial seizures, with no 28 day period free of partial seizures with or without secondary generalization. A caregiver or witness must be with the subject for a sufficient duration to accurately chronicle the occurrence of seizures. These seizures must have been documented in the subject's diary.
• Subjects with electroencephalograph (EEG) testing done within 2 years of randomization. EEG abnormalities should be consistent with a diagnosis of focal-onset epilepsy.
• Signed and dated informed consent will be obtained from each subject (only include those able to consent) in accordance with the local regulatory and legal requirements.
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Subjects who are willing, but need assistance for self administered questionnaires may be considered acceptable, but must first be discussed on a case-by-case basis with the Pfizer monitor prior to any to any screening tests or procedures for the study.

You may not qualify if:

• Females who are pregnant, breastfeeding, or intending to become pregnant during the course of the trial.
• Subjects with other neurologic illness that could impair endpoint assessment, or patients with Lennox-Gastaut syndrome, absence seizures, status epilepticus within the 12 months prior to study entry, or with seizures due to an underlying medical illness or metabolic syndrome.
• Subjects with clinically significant liver disease or with a calculated creatinine clearance of \<60mL/min.
• Subjects with a history of lack of response, hypersensitivity or poor tolerability to gabapentin or pregabalin.
• Previous use of gabapentin or pregabalin within 2 weeks prior to screening or likelihood of engaging in these treatments during the study period.
• Use of prohibited medications as listed in the protocol in the absence of appropriate washout phase or the likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
• Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
• Subjects who are not suitable to be treated with pregabalin or gabapentin according to the respective local labeling.
• Subjects with a history of retinal abnormalities or treatment with retinotoxic agents.

Sponsors & Collaborators

• Pfizer's Upjohn has merged with Mylan to form Viatris Inc.: lead

Study Sites (8)

Hospital Clinica Biblica

San José, Costa Rica

Location

Instituto de Neurociencias

San Salvador, 01503, El Salvador

Location

Clinica de Especialidades Neurologicas

San Salvador, El Salvador

Location

Private Office

Guatemala Ciudad, Departamento de Guatemala, 01014, Guatemala

Location

Private Office

Guatemala City, Guatemala

Location

Clinica Anglo Americana

Lima, 27, Peru

Location

Torre de Consultorios Clinica Anglo Americana

Lima, L-27, Peru

Location

Hospital Nacional Guillermo Almenara Irigoyen - Essalud

Lima, L13, Peru

Location

Related Publications (1)

• French J, Glue P, Friedman D, Almas M, Yardi N, Knapp L, Pitman V, Posner HB. Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology. 2016 Sep 20;87(12):1242-9. doi: 10.1212/WNL.0000000000003118. Epub 2016 Aug 12.

  PMID: 27521437 DERIVED

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Epilepsy; Epilepsies, Partial; Epilepsy, Complex Partial

Interventions

Pregabalin; Gabapentin

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric Acid; Aminobutyrates; Butyrates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Amino Acids; Amino Acids, Peptides, and Proteins; Amines; Cyclohexanecarboxylic Acids; Acids, Carbocyclic; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2007
• First Posted: October 2, 2007
• Study Start: February 1, 2008
• Primary Completion: July 1, 2013
• Study Completion: July 1, 2013
• Last Updated: January 22, 2021
• Results First Posted: August 8, 2014

Record last verified: 2018-11

Locations

EL (2); CO (1); GU (2); PE (3)